S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Forecast, Price & News

$7.72
+0.40 (+5.46%)
(As of 09/26/2023 ET)
Compare
Today's Range
$7.22
$7.96
50-Day Range
$6.66
$10.64
52-Week Range
$6.45
$28.20
Volume
200,103 shs
Average Volume
236,085 shs
Market Capitalization
$450.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.60

IGM Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
205.7% Upside
$23.60 Price Target
Short Interest
Bearish
28.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.63mentions of IGM Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$31,850 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.16) to ($4.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

154th out of 963 stocks

Pharmaceutical Preparations Industry

54th out of 450 stocks


IGMS stock logo

About IGM Biosciences (NASDAQ:IGMS) Stock

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGMS Price History

IGMS Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Why IGM Biosciences (IGMS) Stock Is Trading Higher
See More Headlines
Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IGMS Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IGMS
Fax
N/A
Employees
289
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$23.60
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+205.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-221,100,000.00
Net Margins
-14,007.47%
Pretax Margin
-13,995.76%

Debt

Sales & Book Value

Annual Sales
$1.07 million
Book Value
$6.67 per share

Miscellaneous

Free Float
25,150,000
Market Cap
$450.62 million
Optionable
Not Optionable
Beta
-0.24

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Fred M. Schwarzer J.D. (Age 70)
    CEO, Pres & Director
    Comp: $977.66k
  • Dr. Bruce A. Keyt (Age 70)
    Chief Scientific Officer
    Comp: $692.95k
  • Dr. Chris H. Takimoto FACP (Age 64)
    M.D., Ph.D., Chief Medical Officer
    Comp: $684.95k
  • Mr. Misbah Tahir (Age 48)
    Chief Financial Officer
  • Mr. TS Harigopal
    Sr. VP of Group Operations
  • Mr. Steven Weber (Age 47)
    Sr. VP, Corp. Controller & Principal Accounting Officer
  • Mr. Paul C. Graffagnino
    VP of Legal Affairs
  • Ms. Suzette Tauber (Age 59)
    Chief HR Officer
  • Dr. Angus M. Sinclair Ph.D.
    Sr. VP of Immuno-Oncology
  • Dr. Lisa L. Decker Ph.D. (Age 54)
    Chief Bus. Officer













IGMS Stock - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IGMS shares.
View IGMS analyst ratings
or view top-rated stocks.

What is IGM Biosciences' stock price forecast for 2023?

8 equities research analysts have issued 12 month price objectives for IGM Biosciences' stock. Their IGMS share price forecasts range from $11.00 to $55.00. On average, they predict the company's share price to reach $23.60 in the next twelve months. This suggests a possible upside of 205.7% from the stock's current price.
View analysts price targets for IGMS
or view top-rated stocks among Wall Street analysts.

How have IGMS shares performed in 2023?

IGM Biosciences' stock was trading at $17.01 at the start of the year. Since then, IGMS stock has decreased by 54.6% and is now trading at $7.72.
View the best growth stocks for 2023 here
.

When is IGM Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IGMS earnings forecast
.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) released its earnings results on Thursday, August, 3rd. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.03. The business had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.80 million. IGM Biosciences had a negative trailing twelve-month return on equity of 84.18% and a negative net margin of 14,007.47%. IGM Biosciences's quarterly revenue was up 22.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.33) EPS.

What ETFs hold IGM Biosciences' stock?

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

(IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is IGM Biosciences' stock symbol?

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

Who are IGM Biosciences' major shareholders?

IGM Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Artal Group S.A. (5.85%), RA Capital Management L.P. (1.61%), BlackRock Inc. (1.99%), Goldman Sachs Group Inc. (1.15%), Great Point Partners LLC (0.86%) and State Street Corp (0.45%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg and Misbah Tahir.
View institutional ownership trends
.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IGM Biosciences' stock price today?

One share of IGMS stock can currently be purchased for approximately $7.72.

How much money does IGM Biosciences make?

IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $450.62 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis.

How many employees does IGM Biosciences have?

The company employs 289 workers across the globe.

How can I contact IGM Biosciences?

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873.

This page (NASDAQ:IGMS) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -